1
|
Jadaun GPS, Kalaivani M, Kumar M, Singh GN, Raghuvanshi RS, Jain P. Report of a collaborative study to establish the first Indian Pharmacopoeia reference standard for teriparatide. Biologicals 2024; 86:101755. [PMID: 38479212 DOI: 10.1016/j.biologicals.2024.101755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Revised: 12/19/2023] [Accepted: 02/22/2024] [Indexed: 06/11/2024] Open
Abstract
A collaborative study was conducted to establish the first Indian Pharmacopoeia Reference Standard (IPRS) for teriparatide to be used in quality control testing of marketed products in compliance with the Indian Pharmacopoeia (IP) monograph. The study objective was to evaluate the candidate standard in terms of the WHO International Standard (IS) to assign its content in mg per vial terms. This study involved four laboratories from India and the candidate standard was calibrated against the WHO IS by each participant laboratory using high-performance liquid chromatography (HPLC) assay method per IP monograph. Direct calibration of the candidate standard resulted in an assigned content of 1.02 mg per vial. Based on the study results the candidate standard was judged suitable to serve as the first IPRS for teriparatide for identification and assay by HPLC.
Collapse
Affiliation(s)
| | - M Kalaivani
- Indian Pharmacopoeia Commission, Sector 23, Raj Nagar, Ghaziabad, 201002, India
| | - Mukesh Kumar
- Indian Pharmacopoeia Commission, Sector 23, Raj Nagar, Ghaziabad, 201002, India
| | | | | | - Parveen Jain
- Eli Lilly and Company India (Pvt.) Ltd., Plot 92, Sector 32, Gurugram, 122001, India
| |
Collapse
|
2
|
Uppal A, Koduri CK, Yadlapalli S, Chirmule N, Chakrabarti R, Atouf F. Recommendations for Enhancing Quality and Capability of Indian Biopharmaceutical Industry: Summary of a Workshop. J Pharm Sci 2020; 109:2958-2961. [PMID: 32710904 DOI: 10.1016/j.xphs.2020.07.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 07/14/2020] [Accepted: 07/14/2020] [Indexed: 10/23/2022]
Abstract
The biopharmaceutical industry is undergoing an evolutionary phase with the rise of advanced manufacturing technologies. The regulatory and customer requirements are shifting towards the development of personalized or targeted medicines. With this changing landscape, industry must evaluate the relevance of quality management systems. Over the past two decades, Indian companies have played a significant role in generating access and reducing costs of medicines. The quality management systems that enable the development and manufacturing of biopharmaceuticals require companies to adapt to regulatory requirements of process development, clinical trials, production, and life cycle management. To better understand the status and potential opportunities to enhance the quality management systems of manufacturing biopharmaceuticals, a workshop was organized by United States Pharmacopeia (USP) and Association of Biotechnology Led Enterprises (ABLE). This paper summarizes the recommendations by the panel and participants of the workshop to industry stakeholders, governance bodies, and policymakers. Following points were proposed to strengthen the culture of quality processes in Indian biopharmaceutical industry: i) Inculcating a culture of quality; ii) Effective training programs on quality processes; iii) Focus on quality beyond compliance; iv) Focus on automation and digitization. v) Enhance processes for pharmacovigilance and product life cycle management. vi) Understanding global regulatory processes.
Collapse
Affiliation(s)
- Annu Uppal
- United States Pharmacopeia India Pvt Ltd, Hyderabad, Telangana, India.
| | | | | | | | | | - Fouad Atouf
- United States Pharmacopeial Convention, Rockville, MD, USA
| |
Collapse
|
3
|
Bindra G, Jadaun GPS, Dixit S, Saklani V, Abbas Z, Jain P, Dancheck KB, Borer MW, Kumari M, Kamal CM, Jain R, Singh S. Establishment of the First National Reference Standard for Insulin Lispro: Report of a collaborative study. Biologicals 2019; 58:1-6. [PMID: 30639575 DOI: 10.1016/j.biologicals.2018.10.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Revised: 10/12/2018] [Accepted: 10/15/2018] [Indexed: 11/26/2022] Open
Abstract
The present study was aimed to establish the First National Reference Standard (NRS) for Insulin lispro to allow stakeholders including manufacturer's laboratories, drug testing laboratories, drug regulatory authorities and academic institutions to demonstrate accuracy of the test results and to enable comparison and validation of analytical methods. The candidate standard for Insulin lispro was evaluated in a collaborative study to assign the vial content in order to serve it as NRS to support the Indian Pharmacopoeia (IP) monograph. The candidate standard was calibrated against the Ph. Eur. Insulin lispro reference standard by each of six participant laboratories in India using HPLC assay method as per the requirements of IP monograph. The results indicate that the candidate standard has an average content of 5.79 mg per vial with purity of 99.87%. Based on the study results the candidate standard was judged suitable to serve as the first NRS for Insulin lispro.
Collapse
Affiliation(s)
- Gurminder Bindra
- National Institute of Biologicals, A-32, Sector-62, NOIDA 201309, India.
| | | | - Shruti Dixit
- National Institute of Biologicals, A-32, Sector-62, NOIDA 201309, India
| | - Vandana Saklani
- National Institute of Biologicals, A-32, Sector-62, NOIDA 201309, India
| | - Zafar Abbas
- National Institute of Biologicals, A-32, Sector-62, NOIDA 201309, India
| | - Parveen Jain
- Eli Lilly and Company India (Pvt.) Ltd., Plot-92, Sector-32, Gurugram 122001, India
| | | | | | - Meena Kumari
- National Institute of Biologicals, A-32, Sector-62, NOIDA 201309, India
| | - Charu Mehra Kamal
- National Institute of Biologicals, A-32, Sector-62, NOIDA 201309, India
| | - Renu Jain
- National Institute of Biologicals, A-32, Sector-62, NOIDA 201309, India
| | - Surinder Singh
- National Institute of Biologicals, A-32, Sector-62, NOIDA 201309, India
| | | |
Collapse
|
4
|
The Value of U.S. Pharmacopeial Standards: A Review of the Literature. J Pharm Sci 2018; 107:2611-2617. [PMID: 29908148 DOI: 10.1016/j.xphs.2018.06.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Revised: 05/10/2018] [Accepted: 06/01/2018] [Indexed: 11/22/2022]
Abstract
While there are many standard-setting health care organizations, the United States Pharmacopeial Convention's (USP) role includes the creation of documentary and physical standards for therapeutics, including chemical drugs, excipients, and biologics. Despite the ubiquity of these standards, little work has been carried out to characterize and quantify their value. We reviewed the peer-reviewed and gray literature relevant to such evaluations. The review yielded 36 articles, focused variously on accreditation and other standards in health care, the broad impact of pharmacopeial standards and evaluations of specific USP standards. We did not find any study quantifying the impact of USP or other pharmacopeial standards, but many reports have been published that suggest the utility of USP standards to drug development, quality assurance, and public health. Frequently cited areas of impact include equitably advancing the analytical capabilities of manufacturers; enabling the creation of legally enforceable naming conventions; detecting mislabeled and substandard drugs in the marketplace, especially in the context of increased globalization of drug markets; and facilitating the harmonization of diverse international drug quality standards. Our insights provide opportunities for empiric assessments of the effects of USP standards on important outcomes including their promotion of efficient drug development, market competition, drug quality, and patient safety.
Collapse
|